Brion W. Murray
Pfizer (United States)(US)Université Bourgogne Franche-Comté(FR)Bristol-Myers Squibb (Belgium)(BE)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics
Most-Cited Works
- → SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase(2001)2,554 cited
- → IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation(1997)2,040 cited
- → PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse(2011)1,680 cited
- → Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3(2008)623 cited
- → Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors(2012)548 cited
- → Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19